Tango Therapeutics Inc Forecast, price target & analysts
Tango Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Tango Therapeutics Inc Classifications & Recommendation:
Tango Therapeutics Inc Price Target
| Target Price | $10.71 |
| Price | $7.53 |
| Potential |
42.23%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Tango Therapeutics Inc 2026 .
The average Tango Therapeutics Inc target price is $10.71.
This is
42.23%
register free of charge
$13.65
81.27%
register free of charge
$8.08
7.30%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Tango Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tango Therapeutics Inc stock has an average upside potential 2026 of
42.23%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.07 | 50.66 |
| 15.17% | 20.42% | |
| EBITDA Margin | -340.15% | -349.01% |
| 11.18% | 2.61% | |
| Net Margin | -309.72% | -245.23% |
| 11.21% | 20.82% |
11 Analysts have issued a sales forecast Tango Therapeutics Inc 2025 . The average Tango Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Tango Therapeutics Inc EBITDA forecast 2025. The average Tango Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Tango Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Tango Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.19 | -1.12 |
| 10.19% | 5.88% | |
| P/E | negative | |
| EV/Sales | 12.97 |
11 Analysts have issued a Tango Therapeutics Inc forecast for earnings per share. The average Tango Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Tango Therapeutics Inc...
Current Tango Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 14 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 14 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 05 2024 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
